Safety and Efficacy of High Power Shorter Duration Ablation Guided by Ablation Index or Lesion Size Index in Atrial Fibrillation Ablation: A Systematic Review and Meta-Analysis

Table 1

Baseline characteristics of included studies.

Study

Country

Study type

Treatment group

Patients (n)

Follow (month)

Age (years)

Male (%)

BMI

DM (%)

PAF (%)

LVEF (%)

LAD (mm)

CHA2DS2-VASc

Leo et al. [11]

United Kingdom

Randomized controlled trial

HPSD-LSI 1

20

29

60.1 ± 9.4

60

27.3 ± 5

N/A

40

60.0 ± 9.2

41.4 ± 6.5

1 (IQR: 1–3)

LPLD-LSI 1

20

29

58.9 ± 9.2

95

30.8 ± 4.6

N/A

45

60.0 ± 11.5

43.0 ± 6

1 (IQR: 0–2)

HPSD-LSI 2

20

29

61.3 ± 9.6

70

28.8 ± 4.9

N/A

40

57.9 ± 6.4

43.7 ± 9.3

2 (IQR: 0–4)

LPLD-LSI 2

20

29

55.7 ± 10

70

28 ± 4.85

N/A

30

60.0 ± 10.2

42.4 ± 7.7

1 (IQR: 1-2)

Kaneshiro et al. [19]

Japan

Retrospective cohort trial

HPSD-AI

101

N/A

63 ± 10

76

N/A

N/A

66

N/A

40.8 ± 6.3

N/A

LPLD

170

N/A

61 ± 10

81

N/A

N/A

79

N/A

38.8 ± 6.5

N/A

Berte et al. [17]

Switzerland

Prospective cohort trial

HPSD-AI

80

6

62 ± 9

72

N/A

40

81

58 ± 8

N/A

N/A

LPLD-AI

94

6

63 ± 9

71

N/A

31

79

59 ± 11

N/A

N/A

Okamatsu et al. [12]

Japan

Prospective cohort trial

HPSD-AI1

20

6

65 ± 10

65

N/A

25

65

65 (IQR: 60–71)

40 ± 6

2 (IQR: 1–3)

LPLD-AI

20

6

68 ± 8

75

N/A

5

80

64 (IQR: 60–67)

39 ± 6

2 (IQR: 1‐2)

HPSD-AI2

20

6

64 ± 8

55

N/A

19

75

64 (IQR: 59–71)

40 ± 5

2 (IQR: 1–3)

Castrejon-Castrejon et al. [18]

Spain

Prospective cohort trial

HPSD50w-AI or LSI

18

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

HPSD60w

30

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

LPLD

47

N/A

N/A

60

29 ± 5

N/A

64

56 ± 11

N/A

N/A

Kyriakopoulou et al. [13]

Belgium

Retrospective cohort trial

HPSD-AI

80

12

67 (IQR: 58–73)

59

28 ± 5

N/A

100

N/A

43 ± 8

2 (IQR: 1–3)

LPLD-AI

105

12

64 (IQR: 56–69)

62

27 ± 4

N/A

100

N/A

44 ± 6

2 (IQR: 1‐2)

Dhillon et al. [10]

United Kingdom

Prospective cohort trial

HPSD-AI

50

12

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

LPLD

50

12

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

Values are mean ± SD, median (interquartile range), or n%; N/A, not available; AI, ablation index; BMI, body mass index; CHA2DS2-VASc, cardiac failure or dysfunction, hypertension, age ≥75 (doubled), diabetes, stroke (doubled)-vascular disease, age (65–74), and sex category (female); DM, diabetes mellitus; HPSD, high power and short duration; IQR, interquartile range; LAD, left atrial diameter; LPLD, low power longer duration; LSI, lesion size index; LVEF, left ventricular ejection fraction; PAF, paroxysmal atrial fibrillation.